Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

IJMS, Free Full-Text

Frontiers Phenotypic heterogeneity drives differential disease outcome in a mouse model of triple negative breast cancer

Frontiers Targeting the Nerve Growth Factor Signaling Impairs the Proliferative and Migratory Phenotype of Triple-Negative Breast Cancer Cells

Long Non-Coding RNAs in Triple-Negative Breast Cancer

Frontiers Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer

PDF] Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.

Model identification using representative genes in human

Pharmaceuticals, Free Full-Text

Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer

Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial

Cancers, Free Full-Text

Recent advancements in nanoconstructs for the theranostics applications for triple negative breast cancer - ScienceDirect